Welcome to BioLegend’s one-of-a-kind advanced search. Search by any one of the single fields below or narrow down your searches by using multiple parameters. Looking for an anti-mouse NK cell antibody for IHC? Or looking for a FITC-conjugated antibody against a human marker for dendritic cells to use for flow cytometry? Only BioLegend’s advanced search can provide you with the best answers. If you have further questions, please contact our technical service team at 858-768-5801.
Use this document lookup tool to find Current Product Datasheets, Certificates of Analysis, or MSDS for any antibody products you have purchased from BioLegend.
Use the search box below to perform a site search of BioLegend.com powered by Google™.
Recombinant Mouse IL-27 (carrier-free)
Recombinant Mouse IL-27 (carrier-free)
577402
10 µg
¥49,000
577404
25 µg
¥79,000
577406
100 µg
¥240,000
577408
500 µg
¥800,000
Product Details
Source:
mIL-27 consists of human CD33 signal peptide (Met1-Ala16), mouse EBI3 (NM_015766, Tyr19-Pro228), and mouse p28 (NM_145636, Phe29-Ser234) joined via a GGGSGGGSGGGTGGGS linker, expressed in 293E cells.
Formulation:
0.22 µm filtered protein solution is in 20 mM NaH2PO4, pH 6, 0.60 M NaCl.
Endotoxin Level:
Less than 0.01 ng per µg cytokine as determined by the LAL method.
Preparation:
For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 µg/mL in sterile buffer containing carrier protein such as 1% BSA or HSA or 10% FBS.
Concentration:
10-100 µg sizes are bottled at 0.1 mg/mL. 500 µg and larger sizes are bottled at the concentration indicated on the vial.
Storage & Handling:
Unopened vial can be stored at -20°C for six months or at -70°C for one year. After dilution, the cytokine can be stored at 4°C for one month or -20°C to -70°C for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity:
ED50 = 5 - 10 ng/ml, corresponding to a specific activity of 1.0 - 2.0 x 105 units/mg, as determined by inhibition of IL-2 production induced by mouse IL-27 in mouse splenocytes activated with anti-CD3 and anti-CD28 antibodies.
Inhibition of IL-2 production induced by mouse IL-27 in mouse activated splenocytes.
Description:
IL-27 is a heterodimeric cytokine that consists of EBI3, an IL-12p40-related protein, and p28, an IL-12p35-related polypeptide. IL-27 can be allocated to the IL-6/IL-12 superfamily of cytokines which include also IL-23. This family is defined based on similarities in the structural motifs of the ligands, such as a common four-helix bundle, their receptors, which contain a hematopoietin receptor domain. IL-27 signaling occurs via a receptor complex composed of the signal transducing receptor chains WSX-1 and glycoprotein (gp) 130. Whereas WSX-1 is the IL-27–specific receptor chain, gp130 is the common receptor subunit of IL-6 type cytokines. IL-27 signaling in naïve CD4+ T cells leads to activation and phosphorylation of STAT1 and STAT3.
Other Names:
Interleukin 27, IL-27p28 (IL-30), EBI3
Structure:
Heterodimer
Distribution:
Produced by antigen-presenting cells, including macrophages and dendritic cells.
Function:
IL-27 triggers rapid clonal expansion of antigen-specific naïve human and mouse CD4 T cell. IL-27 promotes the early Th1 differentiation through up-regulation of ICAM-1 and T-bet, and suppresses the differentiation to Th2 and Th17. In addition, IL-27 suppresses the cytokine production by activated CD4+ T cells in vitro, and TNF-α and IL-12 production by macrophages. This suppressive mechanism is considered to be mediated through IL-10. IL-27 plays a dominant function together with TGF-β in generating IL-10-producing anti-inflammatory Tr1 cells. Additionally, IL-27 exerts IFN-like functions in liver cells. IL-27 is predominantly produced early after stimulation of APCs by TLR ligands or infectious agents.
Ligand Receptor:
IL-27Ra (also known as WSX-1 or TCCR) paired with gp130
Interaction:
Activated T cells, resting NK cells, resting NKT cells, hepatoma cells, and hepatocytes.
Antigen References:
1. Pflanz S, et al. 2002. Immunity 16:779. 2. Owaki T, et al. 2005. J. Immunol. 175:2191. 3. Batten M, et al. 2006. Nat. Immunol. 7:929. 4. Villarino VA, et al. 2006. J. Immunol. 176:237. 5. Stumhofer JS, et al. 2007. Nat. Immunol. 8:1363. 6. Awasthi A, et al. 2007. Nat. Immunol. 8:1380. 7. Pot C, et al. 2009. J. Immunol. 183:797. 8. Bender H, et al. 2009. Hepatology 50:585.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
